Dyne Therapeutics, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersWaltham, MA
US patents49
SAM.gov UEIC1XKBDG2CRX4
CAGE code22MM5
Incorporated inDE
- nucleic acid therapies
- rare diseases
- FORCE
- Zeleciment rostudirsen
- DYNE-251
- Zeleciment basivarsen
- DYNE-101
- DYNE-302
- physicians
- investors
Named on the company’s own website, read SEP 9, 2026
Open positions
Openings read from Dyne Therapeutics, INC.’s own job board on Greenhouse, last checked OCT 24, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Associate Director, Analytical DevelopmentDyne Therapeutics, INC. · Waltham, MA · 1110GL - Technical Development · posted OCT 20, 2026
- Director, Government Pricing & Contract OperationsDyne Therapeutics, INC. · Waltham, MA · 3100GL - Value & Access · posted OCT 16, 2026
- Senior Director, Medical Affairs BiostatisticsDyne Therapeutics, INC. · Waltham, MA · 1220GL - Data Analytics · posted OCT 9, 2026
- Associate Director, Financial Planning & Analysis (FP&A)Dyne Therapeutics, INC. · Waltham, MA · 2300GL - Finance · posted OCT 6, 2026
- Director, Cost AccountingDyne Therapeutics, INC. · Waltham, MA · 2300GL - Finance · posted OCT 6, 2026
- Director, RevenueDyne Therapeutics, INC. · Waltham, MA · 2300GL - Finance · posted OCT 6, 2026
- Associate Director, Market Research & Competitive IntelligenceDyne Therapeutics, INC. · Waltham, MA · 3200GL - Commercialization · posted SEP 29, 2026
- Associate Director, Medical Information and ReviewDyne Therapeutics, INC. · Waltham, MA · 4000GL - Medical Affairs · posted SEP 29, 2026
- Senior Director, Financial Planning & Analysis - R&DDyne Therapeutics, INC. · Waltham, MA · 2300GL - Finance · posted SEP 28, 2026
- Senior Administrative Assistant - US AffiliateDyne Therapeutics, INC. · Waltham, MA · 3300US - US Affiliate · posted SEP 17, 2026
21 more on the company’s board
Patents
49 US patents granted 2021–2025, 49 of them in the five years to SEP 2025.
Pharmaceuticals 49
- Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subjectUS 12,428,487 · granted SEP 30, 2025
- Muscle targeting complexes and uses thereof for treating dystrophinopathiesUS 12,403,203 · granted SEP 2, 2025
- Muscle targeting complexes and uses thereof for treating dystrophinopathiesUS 12,397,062 · granted AUG 26, 2025
- Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectUS 12,370,264 · granted JUL 29, 2025
- Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skippingUS 12,357,703 · granted JUL 15, 2025
Newest 5 shown · Granted to Dyne Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Dyne Therapeutics, INC. | Waltham | MA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.